Study of Extracellular Vesicle Tissue Factor Levels and Pulmonary Embolism in Adults with Acute Respiratory Distress Syndrome

What this Trial Is About

Researchers are studying patients with Acute Respiratory Distress Syndrome ARDS to investigate whether the levels of a blood marker called EV-TF are associated with the occurrence of pulmonary embolism. The study will include 120 patients admitted to an intensive care unit over two years. Blood samples will be taken at the start to measure coagulation biomarkers, and patients will be monitored with CT scans to detect pulmonary embolism between days 5 and 28 after inclusion. Patients will receive standard care as per usual hospital practices. They will be divided into two groups based on CT scan results showing either the presence or absence of pulmonary embolism. The main analysis will focus on patients who had a CT scan between days 5 and 7, while a secondary analysis will include those scanned between days 8 and 28. Clinical data will be collected on days 1, 7, 28, and on the day of the CT scan if it occurs at another time. Participants will undergo blood tests to measure specific coagulation factors and biomarkers at inclusion. Researchers will collect clinical information regularly and compare EV-TF levels and other markers between patients with and without pulmonary embolism. The primary outcome is the difference in EV-TF levels at inclusion between these groups at day 7. Secondary outcomes include similar comparisons at day 28 and associations with patient prognosis and lung function. The study will continue to collect data until October 2027.

Association Between the Level of EV-TF and the Occurence of Pulmonary Embolism in Patients With ARDS